Palisade Bio (PALI) Cash from Financing Activities (2010 - 2026)

Palisade Bio (PALI) has 17 years of Cash from Financing Activities data on file, last reported at $3.1 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.1 million, up 1314.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.8 million (up 1788.1% YoY), and the FY2025 annual result was $134.4 million, up 1303.05% from the prior year.
• Cash from Financing Activities declined to $3.1 million in Q1 2026 per PALI's latest filing, from $131.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $131.3 million in Q4 2025 and troughed at -$258000.0 in Q1 2025.
• A 5-year average of $10.2 million and a median of $2.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 5203.45% in 2023, then plunged 112.75% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $1.7 million in 2022, then tumbled by 107.82% to -$134000.0 in 2023, then jumped by 3205.97% to $4.2 million in 2024, then soared by 3055.48% to $131.3 million in 2025, then tumbled by 97.61% to $3.1 million in 2026.
• Business Quant data shows PALI's Cash from Financing Activities at $3.1 million in Q1 2026, $131.3 million in Q4 2025, and $3.4 million in Q3 2025.